Detection of breast cancer stem cell gene mutations in circulating free DNA during the evolution of metastases Zhe-Bin LiuNader E. EzzedineJenny C. Chang Preclinical study 06 August 2019 Pages: 251 - 261
Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer Jichao HeRonan P. McLaughlinBob van de Water Preclinical study Open access 06 August 2019 Pages: 263 - 274
HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor Yuanyuan LiuShafei WuXuan Zeng Preclinical study Open access 06 August 2019 Pages: 275 - 281
Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer Akira I. HidaTakahiro WatanabeAkihide Tanimoto Preclinical study 12 August 2019 Pages: 283 - 294
Evaluation of phospho-histone H3 in Asian triple-negative breast cancer using multiplex immunofluorescence Chi Peng Timothy LaiJoe Poh Sheng YeongPuay Hoon Tan Preclinical study 13 August 2019 Pages: 295 - 305
Genomic landscape of ductal carcinoma in situ and association with progression Chieh-Yu LinSujay VennamRobert B. West Preclinical study 17 August 2019 Pages: 307 - 316
Gene expression analysis to detect disseminated tumor cells in the bone marrow of triple-negative breast cancer patients predicts metastatic relapse Chidananda M. SiddappaSreeraj G. PillaiRebecca Aft Preclinical study Open access 20 August 2019 Pages: 317 - 325
A randomized, double-blind, window of opportunity trial evaluating the effects of chloroquine in breast cancer patients Angel ArnaoutSusan J. RobertsonMark Clemons Clinical trial 07 August 2019 Pages: 327 - 335
A multicentre, randomized pilot trial comparing vascular access strategies for early stage breast cancer patients receiving non-trastuzumab containing chemotherapy Andrew RobinsonCarol Stoberthe REaCT investigators Clinical trial 07 August 2019 Pages: 337 - 345
Randomized window of opportunity trial evaluating high-dose vitamin D in breast cancer patients Angel ArnaoutSusan RobertsonMark Clemons Clinical trial 09 August 2019 Pages: 347 - 356
Phase II randomized controlled trial of hypnosis versus progressive muscle relaxation for body image after breast or gynecologic cancer Debra L. BartonTrevor M. BrooksCatherine H. Van Poznak Clinical trial 09 August 2019 Pages: 357 - 365
Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11) Ji-Yeon KimEunjin Leethe Breast Cancer Committee of the Korean Cancer Study Group Clinical trial 12 August 2019 Pages: 367 - 377
Marital status is an independent prognostic factor in inflammatory breast cancer patients: an analysis of the surveillance, epidemiology, and end results database Yan-ling LiuDun-wei WangZhi-wen Li Clinical trial Open access 14 August 2019 Pages: 379 - 388
Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination Sandra M. SwainGong TangNorman Wolmark Clinical trial Open access 19 August 2019 Pages: 389 - 399
Long-term outcome with targeted therapy in advanced/metastatic HER2-positive breast cancer: The Royal Marsden experience Nicolò Matteo Luca BattistiDaniel TongIan Smith Clinical trial 20 August 2019 Pages: 401 - 408
Reliability of preoperative breast biopsies showing ductal carcinoma in situ and implications for non-operative treatment: a cohort study Gurdeep S. MannuEmma J. GroenJelle Wesseling Epidemiology Open access 06 August 2019 Pages: 409 - 418
Utilization, duration, and outcomes of neoadjuvant endocrine therapy in the United States Ashley C. PariserTannaz SedghiSarah S. Mougalian Epidemiology 10 August 2019 Pages: 419 - 426
Allelic modification of breast cancer risk in women with an NBN mutation Bogna RusakWojciech Kluźniakthe Polish Hereditary Breast Cancer Consortium Epidemiology 13 August 2019 Pages: 427 - 431
Differences in breast cancer outcomes amongst Black US-born and Caribbean-born immigrants Priscila Barreto-CoelhoDanielle CerbonSophia H. L. George Epidemiology 14 August 2019 Pages: 433 - 440
Time-to-surgery and overall survival after breast cancer diagnosis in a universal health system Yvonne L. EaglehouseMatthew W. GeorgKangmin Zhu Epidemiology 14 August 2019 Pages: 441 - 450
Ki-67 (30-9) scoring and differentiation of Luminal A- and Luminal B-like breast cancer subtypes Giuseppe VialeAmy E. Hanlon NewellPatrick Maisonneuve Epidemiology Open access 17 August 2019 Pages: 451 - 458
Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer Christine LundgrenPär-Ola BendahlMaria Ekholm Epidemiology Open access 20 August 2019 Pages: 459 - 467
Rationale for evaluating breast cancers of Lynch syndrome patients for mismatch repair gene expression Steven Sorscher Brief Report 07 August 2019 Pages: 469 - 471
Effect of early adverse events resulting in ado-trastuzumab emtansine dose adjustments on survival outcomes of HER2+ advanced breast cancer patients Ethan TangAndrew RowlandAshley M. Hopkins Brief Report 09 August 2019 Pages: 473 - 477
Precision medicine: PI3K targeting in advanced breast cancer Andrea RoccaElisabetta MelegariMichela Palleschi Letter to the Editor 19 August 2019 Pages: 479 - 479
Letter regarding Sopik V et al. entitled “Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ” Xiangyu WangXiangyi KongJing Wang Letter to the Editor 20 August 2019 Pages: 481 - 482